Clinical Report: Ceftaroline and Carbapenem Combination Restores Activity Against Resistant MRSA

Overview

Ceftaroline-resistant MRSA poses a growing therapeutic challenge. This study demonstrates that combining ceftaroline with carbapenems (ertapenem or meropenem) restores antimicrobial activity against resistant MRSA strains both in vitro and in a murine bacteremia model, suggesting a promising strategy for difficult infections.

Background

Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of persistent bacteremia and endocarditis, with current treatments like vancomycin and daptomycin often limited by suboptimal bactericidal activity or toxicity. Ceftaroline, a fifth-generation cephalosporin targeting PBP2a, has been effective against MRSA but resistance is emerging due to mecA and PBP mutations. Combination therapy with carbapenems has shown potential to enhance activity and suppress resistance, but its efficacy against ceftaroline-resistant MRSA required further evaluation.

Data Highlights

Key Findings

• The ceftaroline-resistant MRSA isolate (AR-0703) showed high MICs for ceftaroline and carbapenems but remained susceptible to vancomycin.
• Checkerboard assays demonstrated synergy between ceftaroline and carbapenems regardless of bacterial inoculum density.
• Time-kill assays confirmed that combination therapy achieved significant bacterial reduction compared to monotherapy under both bacteriologic and physiological conditions.
• In a murine bacteremia model, ceftaroline plus ertapenem significantly reduced kidney bacterial burden compared to controls and single agents.
• Combination therapy suppressed resistance and virulence gene expression and enhanced immune-mediated killing mechanisms.

Clinical Implications

The combination of ceftaroline with carbapenems offers a viable therapeutic option to overcome ceftaroline resistance in MRSA infections, particularly in high-burden or biofilm-associated cases. This strategy may improve outcomes where standard monotherapies fail, warranting further clinical trials to establish safety and efficacy in humans.

Conclusion

Ceftaroline-carbapenem combination therapy effectively restores antimicrobial activity against ceftaroline-resistant MRSA in vitro and in vivo, representing a promising approach to address emerging resistance in difficult MRSA infections.

References

1. Antimicrobial Resistance, Brief Report -- Addressing Ceftaroline Resistance in MRSA Through the Use of Ceftaroline and Carbapenem Combination Therapy